Literature DB >> 19394103

Operational tolerance after liver transplantation.

Giuseppe Orlando1, Shay Soker, Kathryn Wood.   

Abstract

The achievement of an immunosuppression (IS)-free state after transplantation represents the ultimate goal of any immunosuppressive regimen. While clinical operational tolerance (COT) remains the exception after other types of solid organ transplantation, several cases of COT have been described after liver transplantation (LT). Overall, the experience gained so far worldwide demonstrates that COT can be achieved safely in one quarter of selected individuals, irrespective of the immunological background of donor and recipient, patient age, indication for LT, study endpoint, length of the weaning period and of pre/post-weaning follow-up, presence or not of chimerism. However, most transplant physicians still believe that the achievement of COT is still out of reach for the majority of LT recipients because of the potential risk for transplant survival, the non-randomized nature of most of the studies reported so far, and the selective nature of the patients enrolled in such studies, making them non-representative of the whole population of LT recipients. Despite these concerns, the present article demonstrates that this attitude is potentially no longer justified, given the growing evidence that a permanent and stable IS-free state can be achieved in a proportion of individuals who have received a LT for non-immune mediated liver diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19394103     DOI: 10.1016/j.jhep.2009.03.006

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  41 in total

1.  Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant.

Authors:  Richard Danger; Annaïck Pallier; Magali Giral; Marc Martínez-Llordella; Juan José Lozano; Nicolas Degauque; Alberto Sanchez-Fueyo; Jean-Paul Soulillou; Sophie Brouard
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

Review 2.  Antigen-presenting cell function in the tolerogenic liver environment.

Authors:  Angus W Thomson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-11       Impact factor: 53.106

3.  Immune responses against islet allografts during tapering of immunosuppression--a pilot study in 5 subjects.

Authors:  V A L Huurman; C R van der Torren; P Gillard; R Hilbrands; E P M W van der Meer-Prins; G Duinkerken; F K Gorus; F H J Claas; B Keymeulen; D L Roelen; D G Pipeleers; B O Roep
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

Review 4.  Hepatic immune tolerance induced by hepatic stellate cells.

Authors:  Ching-Chuan Hsieh; Chien-Hui Hung; Lina Lu; Shiguang Qian
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

5.  Hepatic Stellate Cells Directly Inhibit B Cells via Programmed Death-Ligand 1.

Authors:  Yan Li; Lina Lu; Shiguang Qian; John J Fung; Feng Lin
Journal:  J Immunol       Date:  2016-01-11       Impact factor: 5.422

Review 6.  Tolerance--is it worth it?

Authors:  Erik B Finger; Terry B Strom; Arthur J Matas
Journal:  Cold Spring Harb Perspect Med       Date:  2014-02-01       Impact factor: 6.915

Review 7.  Will regenerative medicine replace transplantation?

Authors:  Giuseppe Orlando; Shay Soker; Robert J Stratta; Anthony Atala
Journal:  Cold Spring Harb Perspect Med       Date:  2013-08-01       Impact factor: 6.915

Review 8.  The liver works as a school to educate regulatory immune cells.

Authors:  Fenglei Li; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

Review 9.  Immune monitoring as prerequisite for transplantation tolerance trials.

Authors:  K Behnam Sani; B Sawitzki
Journal:  Clin Exp Immunol       Date:  2017-06-23       Impact factor: 4.330

Review 10.  Immunoisolation: where regenerative medicine meets solid organ transplantation.

Authors:  Rajesh Pareta; Brian Sanders; Paurush Babbar; Tom Soker; Christopher Booth; John McQuilling; Sittadjody Sivanandane; Robert J Stratta; Giuseppe Orlando; Emmanuel C Opara
Journal:  Expert Rev Clin Immunol       Date:  2012-09       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.